JP2016521712A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521712A5 JP2016521712A5 JP2016518060A JP2016518060A JP2016521712A5 JP 2016521712 A5 JP2016521712 A5 JP 2016521712A5 JP 2016518060 A JP2016518060 A JP 2016518060A JP 2016518060 A JP2016518060 A JP 2016518060A JP 2016521712 A5 JP2016521712 A5 JP 2016521712A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- nanoparticles
- composition according
- microparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000011859 microparticle Substances 0.000 claims 8
- 239000002105 nanoparticle Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010029113 Neovascularisation Diseases 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000005623 Carcinogenesis Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000002137 anti-vascular effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000036952 cancer formation Effects 0.000 claims 1
- 231100000504 carcinogenesis Toxicity 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000035168 lymphangiogenesis Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 230000008728 vascular permeability Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019006590A JP6931011B2 (ja) | 2013-06-07 | 2019-01-18 | 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832290P | 2013-06-07 | 2013-06-07 | |
| US61/832,290 | 2013-06-07 | ||
| PCT/US2014/041526 WO2014197892A1 (en) | 2013-06-07 | 2014-06-09 | A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019006590A Division JP6931011B2 (ja) | 2013-06-07 | 2019-01-18 | 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016521712A JP2016521712A (ja) | 2016-07-25 |
| JP2016521712A5 true JP2016521712A5 (enExample) | 2017-07-20 |
| JP6470740B2 JP6470740B2 (ja) | 2019-02-13 |
Family
ID=52008639
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016518060A Active JP6470740B2 (ja) | 2013-06-07 | 2014-06-09 | 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム |
| JP2019006590A Expired - Fee Related JP6931011B2 (ja) | 2013-06-07 | 2019-01-18 | 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019006590A Expired - Fee Related JP6931011B2 (ja) | 2013-06-07 | 2019-01-18 | 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9802984B2 (enExample) |
| EP (2) | EP3643318A1 (enExample) |
| JP (2) | JP6470740B2 (enExample) |
| CN (2) | CN105431162B (enExample) |
| AU (1) | AU2014274703B2 (enExample) |
| CA (1) | CA2914764C (enExample) |
| DK (1) | DK3003343T3 (enExample) |
| ES (1) | ES2774217T3 (enExample) |
| HU (1) | HUE047735T2 (enExample) |
| IL (1) | IL242760B (enExample) |
| WO (1) | WO2014197892A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6470740B2 (ja) * | 2013-06-07 | 2019-02-13 | ザ ジョンズ ホプキンス ユニバーシティ | 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム |
| WO2016022947A1 (en) | 2014-08-07 | 2016-02-11 | The Johns Hopkins University | Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases |
| KR101748120B1 (ko) * | 2015-07-13 | 2017-06-16 | 서울대학교산학협력단 | 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도 |
| EP3377080B1 (en) | 2015-11-19 | 2024-02-14 | Asclepix Therapeutics, LLC | Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations |
| WO2018067646A1 (en) * | 2016-10-04 | 2018-04-12 | Asclepix Therapeutics, Llc | Compounds and methods for activating tie2 signaling |
| CA3063140A1 (en) * | 2017-05-08 | 2018-11-15 | Asclepix Therapeutics, Inc. | Biodegradable microparticles for sustained delivery of anti-angiogenic peptide |
| US11674959B2 (en) | 2017-08-03 | 2023-06-13 | The Johns Hopkins University | Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors |
| WO2019075056A1 (en) | 2017-10-10 | 2019-04-18 | The Johns Hopkins University | BIODEGRADABLE BIOMIMETIC PARTICLES |
| US11697804B2 (en) | 2018-10-01 | 2023-07-11 | The Johns Hopkins University | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy |
| WO2020163601A2 (en) * | 2019-02-06 | 2020-08-13 | The University Of North Carolina At Chapel Hill | Compositions and methods for inhibiting post-surgical adhesions |
| CA3134816A1 (en) * | 2019-03-26 | 2020-10-01 | Asclepix Therapeutics, Inc. | Compositions and methods for treating ocular disease |
| US12605463B2 (en) | 2019-04-12 | 2026-04-21 | The Johns Hopkins University | Tolerogenic artificial antigen-presenting cells |
| CN113144213B (zh) * | 2021-03-23 | 2023-04-07 | 西安交通大学医学院第一附属医院 | 一种多级pH响应基因-药物共递送的纳米药物、制备方法及其应用 |
| WO2024044745A2 (en) * | 2022-08-26 | 2024-02-29 | Asclepix Therapeutics, Inc. | Formulations for intraocular delivery of peptides derived from type iv collagen |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009512423A (ja) | 2005-09-12 | 2009-03-26 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 抗血管新生の活性を有する組成物及びその使用 |
| WO2007120368A2 (en) * | 2006-01-09 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
| ITMI20060625A1 (it) * | 2006-03-31 | 2007-10-01 | Istituto Naz Per La Ricerca | Peptide antiangiogenico e suoi impieghi terapeutici |
| CA2666709A1 (en) * | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Method for treating age-related macular degeneration |
| WO2008085828A2 (en) | 2007-01-03 | 2008-07-17 | The Johns Hopkins University | Peptide modulators of angiogenesis and use thereof |
| WO2009135854A2 (en) * | 2008-05-06 | 2009-11-12 | Glaxo Group Limited | Encapsulation of biologically active agents |
| JP2011528566A (ja) * | 2008-07-21 | 2011-11-24 | コンプジェン リミティッド | アンジオポエチン由来ペプチド |
| WO2014066811A1 (en) | 2012-10-25 | 2014-05-01 | The Johns Hopkins University | Bioreducible poly (b-amino ester)s for sirna delivery |
| US9717694B2 (en) * | 2009-05-15 | 2017-08-01 | The Johns Hopkins University | Peptide/particle delivery systems |
| IN2012DN05099A (enExample) | 2009-12-16 | 2015-10-09 | Brigham & Womens Hospital | |
| US20120192339A1 (en) | 2010-07-28 | 2012-08-02 | Honeywell International Inc. | Flexible Body Armor Vest with Breast Plate |
| US20120270770A1 (en) * | 2010-08-03 | 2012-10-25 | Jesse Michael Jaynes | Anti-angiogenic peptides and their uses |
| WO2012079088A2 (en) | 2010-12-10 | 2012-06-14 | The Johns Hopkins University | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
| JP5747312B2 (ja) | 2011-02-24 | 2015-07-15 | コニカミノルタ株式会社 | 活性光線硬化型インクジェットインク及び画像形成方法 |
| US20150272900A1 (en) | 2012-10-26 | 2015-10-01 | The Johns Hopkins University | Layer-By-Layer Approach to Co-Deliver DNA and siRNA via AuNPs: A Potential Platform for Modifying Release Kinetics |
| JP6470740B2 (ja) * | 2013-06-07 | 2019-02-13 | ザ ジョンズ ホプキンス ユニバーシティ | 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム |
-
2014
- 2014-06-09 JP JP2016518060A patent/JP6470740B2/ja active Active
- 2014-06-09 CN CN201480043222.XA patent/CN105431162B/zh not_active Expired - Fee Related
- 2014-06-09 AU AU2014274703A patent/AU2014274703B2/en not_active Ceased
- 2014-06-09 WO PCT/US2014/041526 patent/WO2014197892A1/en not_active Ceased
- 2014-06-09 EP EP19195992.3A patent/EP3643318A1/en active Pending
- 2014-06-09 ES ES14807179T patent/ES2774217T3/es active Active
- 2014-06-09 US US14/896,521 patent/US9802984B2/en active Active
- 2014-06-09 DK DK14807179.8T patent/DK3003343T3/da active
- 2014-06-09 EP EP14807179.8A patent/EP3003343B1/en active Active
- 2014-06-09 HU HUE14807179A patent/HUE047735T2/hu unknown
- 2014-06-09 CA CA2914764A patent/CA2914764C/en active Active
- 2014-06-09 CN CN201911163740.6A patent/CN110981941A/zh active Pending
-
2015
- 2015-11-24 IL IL242760A patent/IL242760B/en active IP Right Grant
-
2017
- 2017-09-22 US US15/712,890 patent/US10774112B2/en active Active
-
2019
- 2019-01-18 JP JP2019006590A patent/JP6931011B2/ja not_active Expired - Fee Related
-
2020
- 2020-08-10 US US16/989,416 patent/US11981754B2/en active Active
-
2024
- 2024-04-08 US US18/629,218 patent/US20240391957A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537985A5 (enExample) | ||
| Yu et al. | Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma | |
| Fang et al. | Macrophage-targeted hydroxychloroquine nanotherapeutics for rheumatoid arthritis therapy | |
| Xu et al. | Development of targeted therapies in treatment of glioblastoma | |
| Durymanov et al. | Exploiting passive nanomedicine accumulation at sites of enhanced vascular permeability for non-cancerous applications | |
| JP2016528202A5 (enExample) | ||
| JP2014533698A5 (enExample) | ||
| Hennig et al. | Nanoparticles for the treatment of ocular neovascularizations | |
| CN109414441A (zh) | 治疗医学障碍的喹唑啉和吲哚化合物 | |
| JP2017534638A5 (enExample) | ||
| CA2914764C (en) | A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis-and lymphangiogenesis-dependent diseases | |
| JP2019529415A5 (enExample) | ||
| HRP20191187T1 (hr) | Terapijske nanočestice koje sadrže terapijsko sredstvo, te postupci njihove proizvodnje i upotrebe | |
| JP2018511327A5 (enExample) | ||
| JP2016530280A5 (enExample) | ||
| JP2019535651A5 (enExample) | ||
| JP2011522792A5 (enExample) | ||
| CN105007939B (zh) | 人抗vegfr-2/kdr抗体 | |
| CN109890420A (zh) | 用于递送治疗剂的血小板组合物和方法 | |
| JP2017503014A5 (enExample) | ||
| JP2017511140A5 (enExample) | ||
| Xu et al. | Combined tumor-and neovascular-“dual targeting” gene/chemo-therapy suppresses tumor growth and angiogenesis | |
| JP2018535224A5 (enExample) | ||
| Arruda et al. | Inhibition of melanoma metastasis by dual‐peptide PLGA NPS | |
| JP2017512194A5 (enExample) |